PF-06952229

Research use only, not for human use.

PF-06952229 is an selective and orally active inhibitor of TGFbR1.

PF-06952229 is an selective and orally active inhibitor of TGFbR1.(In Vivo):In MCF-7 ER+ HER2-xenograft breast cancer tumor model, PF-06952229 (30 mg/kg; gavage) combines with Palbociclib results in an improved inhibition of pSMAD2 and a significant increase in survival.

——

PF-06952229 (oral gavage; 30 mg/kg; twice daily; 21 days) combines with Palbociclib 21 days results in an improved inhibition of pSMAD2 in the MCF7 ER+?xenograft breast cancer tumor model. This combination also leads to a significant increase in survival relative to PF-06952229 monotherapy. Animal Model:MCF-7 ER+?HER2-xenograft breast cancer tumor modelDosage:30 mg/kg Administration:Oral gavage; twice daily; 44 days Result:Resulted in an increase in tumor growth inhibition when combined with Palbociclib.

PF06952229

Others

Other Targets

MRP4| OAT1| OAT3

——

——

1801333-55-0

458.92

C23H24ClFN4O3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (108.95 mM)

CC(C)c1cnc(cc1Nc1ccncc1C(=O)NC(CO)CO)-c1cc(Cl)ccc1F

——

(-20℃)

With Ice Pack

≥ 2 years